Business Wire

Thales pioneers Post Quantum Cryptography with a successful world-first pilot on phone calls

24.2.2023 12:00:00 EET | Business Wire | Press release

Share

Thales, as a worldwide cybersecurity leader, has created the first real-world application of Post Quantum Cryptography (PQC) in its flagship secure ‘Cryptosmart’ mobile app, leveraging 5G SIM for PQC. In the pilot, hybrid cryptography (pre and post quantum crypto) was used in a phone call between two devices to protect the information exchanged during the call. Thales has invested and tested post-quantum cybersecurity technologies over the last decade in order to prepare for these emerging threats.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230224005027/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Thales pioneers Post Quantum Cryptography with a successful world-first pilot on phone calls (Photo: Thales)

Even if today's quantum computer1 prototypes are still far from posing a threat to public key cryptography, it is critical to begin investigating resilient solutions. For example, there is a variant of "store now, decrypt later" attacks that consists in storing today's exchanged data and messages in order to decrypt these messages once Quantum Computers are available. This means the majority of digital infrastructure security based on public key cryptography (PKC) may already be vulnerable to a quantum attack.

Such threats are relevant for scenarios involving highly sensitive information, such as classified information exchanged over an encrypted phone call. To address these threats, Thales created a proof of concept to test the scalability and quality of its solutions, which range from 5G SIM cards to secure communication software.

This first real-world quantum protected mobile solution, which combines Thales' 'Cryptosmart' application and its 5G SIM, employs hybrid cryptography, as recommended by the NIST (National Institute of Standards and Technology). ‘CRYSTALS-Kyber’, one of the four algorithms selected by the NIST2, is the PQC algorithm natively implemented in the 5G SIM and used by Cryptosmart application to encrypt the communication.

“Building defences against threats that do not yet exist may appear to be a daunting task. That is exactly the prospect that the global cybersecurity community faces with the impending arrival of quantum computing. The post-quantum era is still years away, but as quantum computing becomes more prevalent, practicing crypto agility now with such pilots and trials are helping Thales and its customers get prepared” said Philippe KERYER, Executive Vice President Strategy & Technology at Thales.

1 Computers that can perform certain tasks much faster than today's computers on a large scale.
2 https://www.nist.gov/news-events/news/2022/07/nist-announces-first-four-quantum-resistant-cryptographic-algorithms

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations — connectivity, big data, artificial intelligence, cybersecurity and quantum computing — to build a future we can all trust, which is vital to the development of our societies.

The company provides solutions, services and products that help its customers —businesses, organisations and states — in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.

Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.

PLEASE VISIT

Thales Digital Identity & Security
Thales unveils three quantum technologies set to revolutionise the world of tomorrow | Thales Group
Business Data Protection and Cybersecurity | Ercom

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT

Thales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye